Coherus Oncology, Inc.
CHRSDrugs in Pipeline
10
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How CHRS's past catalysts played out
CHS-1420
Plaque Psoriasis
CHS-0214
Plaque Psoriasis
Etanercept
Rheumatoid Arthritis
Toripalimab-tpzi
Squamous Cell Carcinoma
STC-15 monotherapy
Solid Tumor
Toripalimab
Sinonasal Cancer
Casdozokitug
Hepatocellular Carcinoma
Nadunolimab
Metastatic Microsatellite Stable Colorectal Carcinoma
SRF388
Hepatocellular Carcinoma
Toripalimab + Chemotherapy
Head and Neck Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CHS-1420 | Phase 3 | Plaque Psoriasis | - | - |
CHS-0214 | Phase 3 | Plaque Psoriasis | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
Toripalimab-tpzi | Phase 2 | Squamous Cell Carcinoma | - | - |
STC-15 monotherapy | Phase 2 | Solid Tumor | - | - |
Toripalimab | Phase 2 | Sinonasal Cancer | - | - |
Casdozokitug | Phase 2 | Hepatocellular Carcinoma | - | - |
Nadunolimab | Phase 2 | Metastatic Microsatellite Stable Colorectal Carcinoma | - | - |
SRF388 | Phase 2 | Hepatocellular Carcinoma | - | - |
Toripalimab + Chemotherapy | Phase 2 | Head and Neck Cancer | - | - |
Hepatocellular Carcinoma
2 drugs in this indication
Plaque Psoriasis
2 drugs in this indication
Rheumatoid Arthritis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Coherus Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Coherus Oncology, Inc.'s (CHRS) pipeline across Phase 3, Phase 2. Its lead program is CHS-1420 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Coherus Oncology, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Coherus Oncology, Inc. (CHRS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CHRS biotech catalysts?→
Add CHRS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Coherus Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.